Pharma
The Paradigm Shift: Navigating the emergence of value-based contracts for future gene therapies
Value-based contracting (VBC) has been difficult to execute in the pharmaceutical arena, especially in the gene therapy space. This has been driven by several factors, including the lack of long-term data, the imbalance of upside and downside risk between manufacturers and payers, and d...
Redundancy: A Golden-Ticket Opportunity
Providing support and strategies for individuals whose roles were made redundant in the Biopharma, Medical Devices, and Health Tech industries ...
Celebrating our Centres – London UCLH
This week we spoke to the team in London at BioResource Centre UCLH about what they’ve been working on and their priorities ahead. Learn about PPIE activity, what various members of the team have to say, how volunteer data is being used, and plans to engage underrepresented groups in th...
Celebrating our Centres - Leicester
This week we spoke to the team at the NIHR BioResource Centre Leicester about community engagement events at supermarkets to promote participation in research. In tandem, we also learn about Leicester’s very own NHS Trust Chief Executive, who has made a personal commitment to health res...
Happy 3rd Birthday to The Eating Disorders Genetics Initiative (EDGI) UK!
The Eating Disorders Genetics Initiative in the UK (EDGI UK) was launched 3 years ago, recruiting members of the public who have experienced any eating disorder. We spoke to the team to find out what's happened since the launch in 2020, achievements to date, who they've collaborated wit...
Sickle Cell Awareness Month 2023 – urgent plea for more donors of Black heritage
During this year’s Sickle Cell Awareness Month, the NHSBT urgently plea for 12,000 new Black donors, as demand from hospitals continues to grow. We discuss our contributions to blood disorder research, hailing the involvement from our volunteers and the importance of representation of d...
Strategies for combination therapy in oncology: Part one – Business as usual
This is the first in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In this article, we discuss the challenges and opportunities within the current landscape and key issues impacting pricing and access for comb...
Strategies for combination therapy in oncology: Part two - Working with the “status quo”
This is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In this article, we investigate strategies that manufacturers could consider to optimize pricing and access opportunities for their c...
Antimicrobial Resistance Policy Solutions
It is difficult to imagine someone who hasn’t called on antibiotics to help them through an infection or protect them during a surgery. Thanks to developments over the last 150 years, once life-threatening bacterial encounters have been relegated to minor inconveniences. Or have they? T...
Get to know the inflammatory bowel disease (IBD) team at the NIHR BioResource
Who are they, what a day looks like in the team and everything involved in making our Inflammatory Bowel Disease (IBD) team one of the core cogs in the workings of the NIHR BioResource! ...